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Monocarboxylate transporters (MCTs) are important cellular pH regulators in cancer cells; however, the value of MCT expression
in cancer is still poorly understood. In the present study, we analysed MCT1, MCT2, and MCT4 protein expression in breast,
colon, lung, and ovary neoplasms, as well as CD147 and CD44. MCT expression frequency was high and heterogeneous among the
diﬀerent tumours. Comparing with normal tissues, there was an increase in MCT1 and MCT4 expressions in breast carcinoma and
a decrease in MCT4 plasma membrane expression in lung cancer. There were associations between CD147 and MCT1 expressions
in ovarian cancer as well as between CD147 and MCT4 in both breast and lung cancers. CD44 was only associated with MCT1
plasma membrane expression in lung cancer. An important number of MCT1 positive cases are negative for both chaperones,
suggesting that MCT plasma membrane expression in tumours may depend on a yet nonidentified regulatory protein.
1. Introduction
Uncontrolled tumour cell proliferation is a pivot mechanism
in tumourigenesis, which consequently leads to significant
metabolic changes. In tumour cells, the preference by anaer-
obic glycolysis, even in the presence of oxygen, phenomenon
known as “the Warburg eﬀect”, stimulates the conversion of
pyruvate to lactic acid [1, 2]. To allow proliferation through
continuous glycolysis and avoid acid-induced apoptosis,
cells must develop mechanisms to oppose the increased
generation of lactic acid. Thus, several plasma membrane
transporters and exchangers have been implicated in the
maintenance of the intracellular pH of cancer cells, by
exporting the accumulating acid, leading to acidification of
the extracellular milieu [3]. Currently, it is acknowledged
that this acidic tumour microenvironment is associated with
tumour aggressiveness features, such as growth advantage,
increased survival, migration, invasion, and angiogenesis
[1, 4].
Monocarboxylate transporters (MCTs) are among the
most important cellular pH regulators likely involved in
cancer pH homeostasis [3, 5]. The MCT family comprises
fourteen members, being the isoforms 1, 2, 3, and 4
responsible for the H+-linked transport of monocarboxylates
such as lactic acid across the plasma membrane [6]. The
underlying molecular events involved in MCT regulation are
poorly understood; however, it was recently demonstrated
that proper plasma membrane expression and activity of
MCTs, particularly MCT1 and MCT4, require the presence
of a chaperone, CD147 [7–9], also known as EMMPRIN
and basigin. Interestingly, CD147 expression seems to be
also dependent on MCT1 and MCT4 expressions [10, 11].
Most recently, it was suggested that constitutive interactions
between hyaluronan and CD44 also contribute to regulation
of MCT localization and function [12]. In the past few
years, some studies reported abnormal expression of MCTs,
particularly MCT1, 2, 3, and 4 in distinct solid tumours,
however, with contradictory conclusions [13–24]. Besides
2 Journal of Biomedicine and Biotechnology
acting as MCT chaperone, CD147 plays many other roles,
including production of matrix metalloproteinases and
vascular endothelial growth factor, being upregulated in a
variety of human cancers [25–28]. Additionally, activation of
CD44 has been described as important in various aspects of
cancer progression including cell growth control, adhesion,
migration, invasion, and chemoresistance [29, 30].
The aim of the present study was to perform a com-
prehensive analysis of MCT1, MCT2, and MCT4 protein
expression in a variety of tumours, namely, breast, colon,
lung, and ovary neoplasms in order to elucidate their pattern
of expression and their role in the development of these
tumours. In addition, CD147 and CD44 expressions were
analysed to infer the contribution of these chaperones to
MCT expression in these diﬀerent tumours.
2. Materials and Methods
2.1. Cases. A commercial human multitumour tissue
microarray (TARP) (NCI Tumour Repository MTA, MD,
USA), containing 200 tumour samples, was used to perform
the immunohistochemical reactions, corresponding to 50
breast carcinomas (42 ductal, 5 lobular, and 3 not clas-
sified), 50 colon adenocarcinomas, 50 nonsmall cell lung
cancers, and 50 ovarian adenocarcinomas (32 serous, 8 clear
cell, 4 mucinous, 4 endometrioid, and 2 not classified).
Additionally, to allow comparison between nonneoplastic
and malignant tissues, 15 normal breast samples and 11
normal lung samples were included in the analysis. Since
ovarian normal tissues are not readily available, they were
not included in this study. MCT expression in nonneoplastic
colon epithelia was already described by our group [19].
2.2. Immunohistochemistry
2.2.1. MCT Detection. Immunohistochemistry was per-
formed according to the avidin-biotin-peroxidase complex
principle (R.T.U. VECTASTAIN Elite ABC Kit (Univer-
sal), Vector Laboratories, Burlingame, CA, USA), with
the primary antibodies for MCT1 (AB3538P, Chemicon
International, Temecula, CA, USA), MCT2 (sc-14926, Santa
Cruz Biotechnology, Santa Cruz, CA, USA), and MCT4
(AB3316P, Chemicon International, Temecula, CA, USA),
diluted 1 : 200 for both MCT1 and MCT2 and 1 : 100 for
MCT4, as previously described by our group [18, 19].
2.2.2. CD147 Detection. Immunohistochemistry was per-
formed according to the avidin-biotin-peroxidase complex
principle (Ultravision Detection System Anti-polyvalent,
HRP, Lab Vision Corporation, Fremont, CA, USA), using a
primary antibody raised against CD147 (18-7344, ZYMED
Laboratories Inc., South San Francisco, CA, USA) diluted
1 : 750, as previously described by our group [31].
2.2.3. CD44 Detection. Immunohistochemistry was per-
formed according to the avidin-biotin-peroxidase complex
principle (Ultravision Detection System Anti-polyvalent,
HRP, Lab Vision Corporation, Fremont, CA, USA), using
CD44s (83 KDa)
CD147 FG (45–65 KDa)
CD147 CG (35 KDa)
Figure 1: Western-blot for CD44 (breast cancer cell line MDA
MB 231) and CD147 (human colon tissue). The protein molecular
weights observed are in accordance with the predicted for these
proteins. FG: fully glycosylated, CG: core glycosylated.
a primary antibody raised against total CD44 (clone 156-
3C11, Cell Signalling Technology, Beverly, MA, USA), diluted
1 : 100. Briefly, deparaﬃnised and rehydrated sections were
immersed in 0.01 M citrate-buﬀered solution (pH 6.0),
heated up to 98◦C in a water bath for 15 minutes, and
washed in PBS. Endogenous peroxidases were inactivated
with 3% hydrogen peroxide in methanol for 10 minutes,
followed by washing in PBS. Tissue sections were incu-
bated with blocking solution for 10 minutes and incubated
at room temperature with the primary antibody for 30
minutes. Sections were then sequentially washed in PBS,
incubated with biotinylated goat anti-polyvalent antibody
for 10 minutes, streptavidin peroxidase for 10 minutes, and
developed with 3,3′-diamino-benzidine (DAB+ Substrate
System, Dako, Carpinteria, CA, USA) for 10 minutes. Neg-
ative controls were performed by using the adequate serum
control (N1698, Dako, Carpinteria, CA, USA) and tonsil was
used as positive control. Tissue sections were counterstained
with haematoxylin and permanently mounted.
The specificity of CD147 and CD44 antibodies was
further demonstrated by Western-blot, as shown in Figure 1.
Antibodies for the MCT isoforms have been previously
validated by our group by Western-blot [19].
2.2.4. Immunohistochemical Evaluation. MCTs, CD147, and
CD44 immunoreactions were evaluated semiquantitatively
using the criteria previously described [19, 31]. Immunore-
action extent was scored semiquantitatively as follows: 0:
0% of immunoreactive cells, 1: <5% of immunoreactive
cell, 2: 5%–50% of immunoreactive cells, and 3: >50% of
immunoreactive cells. Also, intensity of staining was scored
semi-qualitatively as 0: negative, 1: weak, 2: intermediate,
and 3: strong. Immunoreaction final score was defined as the
sum of both parameters (extent and intensity), and grouped
as negative (scores 0 and 2) and positive (3–6). Finally,
since plasma membrane location is essential for MCT1 and
MCT4 membrane localization and activity, we also analysed
the plasma membrane positive cases separately. Evaluation
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Table 1: Frequency of MCTs, CD147, and CD44 expressions in tumour samples.
Tumour type
Expression
MCT1 MCT2 MCT4 CD147 CD44
Positive (%) Positive (%) Positive (%) Positive (%) Positive (%)
n Cyta PM n Cyta PM n Cyta PM n Cyta/PM n Cyta/PM
Breast carcinoma 22 21 (95.5) 5 (22.7) 24 34 (100.0) 0 (0.0) 24 19 (79.2) 1 (4.2) 28 13 (46.4) 27 8 (29.6)
Colon adenocarcinoma 32 23 (71.9) 19 (59.4) 29 29 (100.0) 0 (0.0) 26 19 (73.1) 0 (0.0) 34 13 (38.2) 31 4 (12.9)
Nonsmall cell lung cancer 23 14 (60.9) 5 (21.7) 21 21 (100.0) 0 (0.0) 23 16 (69.6) 0 (0.0) 28 13 (46.4) 27 12 (44.4)
Ovarian adenocarcinoma 24 18 (75.0) 10 (41.7) 30 18 (93.3) 0 (0.0) 28 13 (46.4) 1 (3.6) 26 11 (42.3) 28 2 (7.1)
Cyt: cytoplasm; PM: plasma membrane; awith or without plasma membrane staining.
Note: for CD147 and CD44, frequency results are the same for cytoplasm and plasma membrane expression.
(a) (b) (c)
(d) (e) (f)
Figure 2: Representative immunohistochemical expression of MCT1 in ovarian carcinoma (a), MCT2 in breast carcinoma (b), MCT4 in
ovarian carcinoma (c), CD147 in ovarian carcinoma (d), MCT1 in lung cancer (e), and CD44 in lung cancer (f). Plasma membrane staining
for both MCT1 (a) and CD147 (d) is shown in the same tumour area of an ovary cancer case and for both MCT1 (e) and CD44 (f) in the
same area of lung cancer case.
was performed blindly by two independent observers (AL,
FS). Discordant results were discussed in a double-head
microscope and a final score was agreed.
2.3. Statistical Analysis. Data were stored and analysed
using the SPSS statistical software (version 16.0, SPSS Inc.,
Chicago, IL, USA). All comparisons were examined for
statistical significance using Pearson’s Chi-square (χ2) test
and Fisher’s exact test (when n < 5), being threshold for
significance P values <.05.
3. Results
From the 200 tumour samples, only approximately 60%
were suitable for analysis. The remaining tumour spots
were missing, dropped out during immunohistochemistry
protocol, or did not contain representative tissue, with
some heterogeneity between TARP slides. Tumour samples
were assessed for MCT1, MCT2, MCT4, CD147, and CD44
immunohistochemical expressions and the results are sum-
marised in Table 1. Positive MCT1 expression was observed
in both plasma membrane and cytoplasm (Figures 2(a) and
2(e)), while MCT2 expression was only observed in the
cytoplasm (Figure 2(b)) and MCT4 was commonly found in
the cytoplasm (Figure 2(c)) and rarely in the plasma mem-
brane. Regarding CD147 and CD44, expression was always
present in the plasma membrane (Figures 2(d) and 2(f),
resp.), with some cytoplasmic staining. There was a strong
tendency for diﬀerences in MCT1 and MCT4 expression
frequencies among the diﬀerent tumours (P = .056 and
P = .061, resp.); however, diﬀerences were only significant
when considering MCT1 plasma membrane staining (P =
.012), being highest for colon, followed by ovary. MCT2
and CD147 expression frequencies were not significantly
diﬀerent among the tumour types studied. CD44 expression
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Table 2: Frequency of MCTs expression in nonneoplastic and malignant breast and lung tissues.
Breast tissues Lung tissues
Cyta PM Cyta PM
n Positive (%) P Positive (%) P n Positive (%) P Positive (%) P
MCT1 .001 .067 1 .612
Normal 15 7 (46.7) 0 (0.0) 6 4 (66.7) 2 (33.3)
Tumour 22 21 (95.5) 5 (22.7) 23 14 (60.9) 5 (21.7)
MCT2 .142 .300
Normal 15 13 (86.7) 9 8 (88.9)
Tumour 24 24 (100.0) 21 21 (100.0)
MCT4 .004 1 .289 .001
Normal 15 5 (33.3) 0 (0.0) 6 6 (100.0) 4 (66.7)
Tumour 24 19 (79.2) 1 (4.2) 23 16 (69.6) 0 (0.0)
Cyt: cytoplasm; PM: plasma membrane; awith or without plasma membrane staining.
was also significantly diﬀerent among tumours (P = .004),
being more frequent in lung, followed by breast. Overall,
and looking at each tumour entity, we observed that MCT2
was the most frequently expressed MCT isoform, followed
by MCT1 and 4. MCT1 exhibited the highest frequency of
staining at the plasma membrane, while MCT4 was barely
present and MCT2 was absent.
Comparison of MCT expression frequencies in breast
and lung malignant tissues with the corresponding normal
tissues is depicted in Table 2. In breast carcinomas, there was
a significant increase in MCT1 and MCT4 staining (P = .001
and P = .004, resp.), while in lung cancer, there was a
significant decrease in MCT4 plasma membrane expression
(P = .001).
In order to assess the association of CD147 and CD44
to MCT expression in tumours, we searched for associations
among expressions of these proteins (Tables 3 and 4). Over-
all, considering all tumour entities, both MCT1 and MCT4
immunoreactions correlated with CD147 (P = .001 and
P < .001, resp.), while, for plasma membrane localisation,
this association was only observed for MCT1 (P = .025),
as illustrated in Figures 2(a) and 2(d). No association
was observed between CD147 and MCT2. Considering the
diﬀerent tumours individually, associations between CD147
and MCT4 immunoreaction were only observed in breast
and lung cancers (P = .024 and P = .023, resp.); however,
other values showed a tendency for significance but the
low number of cases limited statistical power. Regarding
CD44, the only significant association was with MCT1
plasma membrane expression in lung cancer (P = .039), as
illustrated in Figures 2(e) and 2(f). Importantly, among the
36 cases positive for MCT1 plasma membrane expression,
12 were negative for both CD147 and CD44 (data not
shown).
4. Discussion
Upregulation of glycolysis and adaptation to acidosis are key
events in the transition from in situ to invasive cancer [1] and
MCTs may play an important role through their involvement
in exporting lactate [6]. MCTs have been described to be
up-regulated in several cancers [13–19]; however, there are
still some controversies [22, 23]. Moreover, their regulation
in cancer is starting to be unravelled.
In the present study, we observed a high and hetero-
geneous frequency of MCT expression among the diﬀer-
ent tumour entities. Importantly, only MCT1 presented a
relevant expression at the plasma membrane, a fact which
is essential for lactate transporter activity. It appears that
the pair MCT1/CD147 is the most relevant in the tumours
studied, likely by promoting lactate eﬄux from cancer
cells. Lactate eﬄux allows continuous proliferation, avoiding
apoptosis by intracellular acidification, thus conferring a
proliferative advantage to cancer cells [1, 4]. The high
frequencies of MCT2 and MCT4 in the cytoplasm might
mean that they are involved in other functions in the
cell, such as in lactate/pyruvate transport through the
mitochondrial/peroxisomal membrane. Actually, MCT2 and
MCT4, as well as MCT1, have been described to be present
in the mitochondrial membrane [32–34].
In the present study, we showed that MCT1 is upreg-
ulated in breast carcinomas, which does not corroborate a
previous report in breast cancer, pointing to a possible silenc-
ing of MCT1 expression by gene promoter hypermethylation
[10, 22]. However, this study only presented the results of
MCT1 promoter methylation and was not supported by
MCT1 protein expression. Taking into consideration that
MCT2 is not present in the plasma membrane and MCT4
is expressed at low levels, it is reasonable to hypothesise that
MCT1 is the main isoform responsible for lactate plasma
membrane transport in breast carcinoma. To confirm this
hypothesis, we are currently evaluating MCT expression in
a larger series of breast carcinomas. The important role
of MCTs in substrate transport in colonic epithelium has
been vastly studied [23, 24, 35–38]. However, data on MCT
expression in colorectal carcinoma are still contradictory
[17, 19, 23, 24]. Our findings on MCT expression are
in agreement with our previous report [19] in which we
described MCT upregulation, especially MCT1 and MCT4.
Comparative studies on lung cancer showed an absent
MCT expression in normal lung but a high MCT plasma
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Table 3: Correlations between MCTs and CD147 expressions in tumours.
CD147 expression
Breast Colon Lung Ovary
n Positive (%) P n Positive (%) P n Positive (%) P n Positive (%) P
MCT1
Cytoplasma .381 .184 .074 .245
Negative 1 0 (0.0) 7 1 (14.3) 8 2 (25.0) 3 0 (0.0)
Positive 20 13 (65.0) 21 11 (52.4) 14 10 (71.4) 15 7 (46.7)
Plasma membrane .131 .114 1 .050
Negative 17 9 (52.9) 10 2 (20.0) 17 9 (52.9) 9 1 (11.1)
Positive 4 4 (100.0) 18 10 (55.6) 5 3 (60.0) 9 6 (66.7)
MCT4
Cytoplasma .024 .118 .023 .214
Negative 4 0 (0.0) 5 0 (0.0) 6 1 (16.7) 12 3 (25.0)
Positive 19 13 (68.4) 19 9 (47.4) 16 12 (75.0) 12 7 (58.3)
Plasma membrane 1 — — 1
Negative 22 12 (54.5) 24 9 (37.5) 22 13 (59.1) 23 10 (43.5)
Positive 1 1 (100.0) 0 — 0 — 1 0 (0.0)
a
with or without plasma membrane staining.
Table 4: Correlations between MCTs and CD44 expressions in tumours.
CD44 expression
Breast Colon Lung Ovary
n Positive (%) P n Positive (%) P n Positive (%) P n Positive (%) P
MCT1
Cytoplasma .364 .218 1 .250
Negative 1 1 (100.0) 6 2 (33.3) 9 3 (33.3) 5 1 (20.0)
Positive 21 7 (33.3) 20 2 (10.0) 13 5 (38.5) 15 0 (0.0)
Plasma membrane .309 .591 .039 1
Negative 17 5 (29.4) 9 2 (22.2) 17 4 (23.5) 10 1 (10.0)
Positive 5 3 (60.0) 17 2 (11.8) 5 4 (80.0) 10 0 (0.0)
MCT4
Cytoplasma 1 .539 .613 .482
Negative 4 1 (25.0) 5 1 (20.0) 6 1 (16.7) 13 2 (15.4)
Positive 18 6 (33.3) 18 2 (11.1) 15 6 (40.0) 11 0 (0.0)
Plasma membrane .318 — — 1
Negative 21 6 (28.6) 23 3 (13.0) 21 7 (33.3) 23 2 (8.7)
Positive 1 1 (100.0) 0 — 0 — 1 0 (0.0)
a
with or without plasma membrane staining.
membrane expression in cancer cells, especially MCT1
[16]. Although at a significantly lower level (20% versus
100%) we also detected MCT1 in the membrane of cancer
cells, the same was not observed for MCT2 and MCT4.
Therefore, it appears that MCT1 is the most important MCT
isoform likely involved in lactate eﬄux from lung cancer
cells. To the best of our knowledge, there are no reports
on MCT expression in ovarian cancer. Thus, the results
here presented are novel and may shed some light onto
the metabolic alterations occurring in this type of cancer.
Indeed, the upregulation of glycolytic enzymes in ovarian
cancer [39–41] points to an increased production of lactate
and, consequently, to the need for upregulation of lactate
transport. In harmony with this line of evidence, we found
a relevant MCT1 expression in ovarian carcinoma, which
warrants further studies on MCT expression in this type of
carcinoma.
Importantly, we assessed the association between MCTs
and the glycoproteins CD147 and CD44 in human tumour
samples. We observed a close association between CD147
expression and MCT1 and MCT4 isoforms, which cor-
roborates the data from the literature stating that CD147
is essential for MCT1 and MCT4 regulation [7, 9, 10]
and that CD147 maturation and cell surface expression is
dependent on MCT1 and MCT4 [10, 11]. It is important to
note that these associations were not homogeneous among
tumour entities, which might indicate that regulation of
these proteins diverges from tumour to tumour. Thus,
additional studies are necessary to unveil the possible
synergism between MCT and CD147 in malignant pro-
gression of tumours from diﬀerent origins. Since it was
recently described that CD44 was also involved in MCT
regulation in breast cancer [12], we analysed MCT and
CD44 coexpression. However, we only found an association
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between CD44 and MCT1 plasma membrane expression in
lung cancer. Notably, we observed that there are still an
important number of cases positive for MCT1, which are
negative for both CD147 and CD44, suggesting that MCT1
plasma membrane expression in tumours may depend on a
yet nonidentified regulatory protein.
In summary, we analysed the expression of MCT1,
MCT2, MCT4, CD147, and CD44 in diﬀerent primary
tumours. Importantly, we evaluated for the first time MCT
expression in ovarian carcinoma and the association between
MCT and both CD147 and CD44 expressions in four
diﬀerent types of tumours. The results herein presented can
contribute to understanding of MCTs’ regulation and role in
human tumours. Nevertheless, additional studies, including
larger and well-characterized tumour series, especially of
breast and ovary, will definitely complement this work and
pave the way to the possible exploitation of MCTs as targets
for cancer therapy.
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